logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Lundbeck Pharmaceuticals LLC drugs

    FiltersReset Filters
    6 results

    • northera

      (droxidopa)
      Lundbeck Pharmaceuticals LLC
      Usage: NORTHERA is indicated for treating orthostatic dizziness and lightheadedness in adults with symptomatic neurogenic orthostatic hypotension due to conditions like Parkinson's disease, multiple system atrophy, and autonomic neuropathy. Its effectiveness beyond two weeks is not established and should be assessed periodically.

    • onfi

      (clobazam)
      Lundbeck Pharmaceuticals LLC
      Usage: ONFI® (clobazam) is indicated as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older.

    • sabril

      (vigabatrin)
      Lundbeck Pharmaceuticals LLC
      Usage: SABRIL is indicated as adjunctive therapy for adults and pediatric patients (2 years and older) with refractory complex partial seizures and as monotherapy for pediatric patients (1 month to 2 years) with infantile spasms. Both uses consider the potential benefits versus the risk of vision loss.

    • sabril

      (vigabatrin)
      Lundbeck Pharmaceuticals LLC
      Usage: SABRIL is indicated as adjunctive therapy for refractory complex partial seizures in patients aged 2 and older who have not responded to other treatments, and as monotherapy for infantile spasms in pediatric patients aged 1 month to 2 years, weighing the potential benefits against the risk of vision loss.

    • vyepti

      (eptinezumab-jjmr)
      Lundbeck Pharmaceuticals LLC
      Usage: VYEPTI is indicated for the preventive treatment of migraines in adults.

    • xenazine

      (tetrabenazine)
      Lundbeck Pharmaceuticals LLC
      Usage: XENAZINE is indicated for treating chorea associated with Huntington's disease.